Fig. 6

METTL3 mediates lncRNA CRNDE m6A modification to inhibit OGD/R-induced neuronal cell apoptosis. (A) m6A quantification assay to determine m6A levels in cells and brain injury tissues. (B) MeRIP assay to measure m6A modification levels of lncRNA CRNDE in cells and brain injury tissues. (C) RIP assay to detect lncRNA CRNDE precipitation. (D) MeRIP analysis of m6A modification levels of lncRNA CRNDE. (E) Expression levels of METTL3 and lncRNA CRNDE. (F) Flow cytometry analysis of apoptosis rate. (G) Western blot analysis of Bcl-2, Bax, and Caspase-3 proteins. (H) ELISA measurement of inflammatory factors TNF-α, IL-1β, IL-6, and IL-10. (I) qRT-PCR analysis of levels of ATG10, LC3, Beclin1, and p62. (J) Western blot analysis of ATG10, LC3II/I, Beclin1, and p62 proteins. *P < 0.05 indicates a significant difference compared to the oe-NC, Control, or Sham group. #P < 0.05 indicates a significant difference compared to the oe-METTL3 + oe-NC group. All data are expressed as Mean ± SD. Comparisons between two groups were performed using the unpaired Student’s t-test, while one-way ANOVA and Tukey’s post-hoc test were used for comparisons among multiple groups. All the experiments were repeated thrice